Is Intermittent Androgen Suppression Becoming the New Standard in Recurrent Prostate Cancer?

Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]

Announcing A Phase 2 Clinical Trial of MDV3100 in Hormone-Naive Prostate Cancer Patients

For our European readers who have not yet started, but are getting ready to start hormone deprivation therapy (ADT), there is a new clinical trial you should consider. This trial is evaluating MDV3100 monotherapy as the first hormonal treatment of patients with prostate cancer. Enrolled men would not have had any previous hormonal therapies for [...]

Blood Glucose and Cholesterol Levels Change Due to ADT in Men with Non-Metastatic Prostate Cancer

We often talk about the assumed fact that androgen deprivation therapy (ADT) changes both the blood glucose levels as well as cholesterol levels in men who are under treatment. Researchers at the Division of General Internal Medicine & Clinical Epidemiology, University Health Network, University of Toronto, Toronto, ON. decided to formally evaluate this theory over [...]

A Confirmatory Study – Acupuncture Provides Relief for Men on ADT

Another small confirmatory study of acupuncture to treat the side effects of hormone deprivation (ADT) was published in the International Journal of Radiation Oncology. The study found that acupuncture appears to provide long-lasting relief to hot flashes, heart palpitations, and anxiety due to side effects of hormone treatment for prostate cancer. […]

Changing ADT in the Treatment of Prostate Cancer – Are We Using It Correctly?

Patient advocates have long raised the question about the wisdom in using hormone therapy for extended periods of time. The introduction of intermittent scheduling of hormone therapy (ADT) has become more acceptable thanks to the questions raised by the community and the support of some oncologists who have been willing to think out of the [...]

Go to Top